The role of ezetimibe in the treatment of cardiovascular disease

Anandita Agarwala; Zaid Kajani; Michael D. Miedema; Salim S. Virani

doi:10.1007/s11883-016-0560-y

The role of ezetimibe in the treatment of cardiovascular disease

Anandita Agarwala
, Zaid Kajani
, Michael D. Miedema
, Salim S. Virani

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Despite the success of treatment of CVD with statin therapy, a number of patients remain at high risk for CVD. Ezetimibe is a non-statin agent that inhibits intestinal cholesterol absorption, leading to reductions in low-density lipoprotein cholesterol (LDL-C). A number of clinical studies evaluating the use of ezetimibe therapy have resulted in discordant data regarding its safety and efficacy. In this review, we discuss the findings from these studies as well as potential indications for the use of ezetimibe for LDL-C lowering and cardiovascular event reduction.

Original language	English (UK)
Article number	8
Journal	Current Atherosclerosis Reports
Volume	18
Issue number	2
DOIs	https://doi.org/10.1007/s11883-016-0560-y
Publication status	Published - Feb 2016
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cardiovascular disease
Ezetimibe
Low-density lipoprotein cholesterol

Access to Document

10.1007/s11883-016-0560-y

Cite this

@article{dbb824594ff047a181be7439a2c0de7f,

title = "The role of ezetimibe in the treatment of cardiovascular disease",

abstract = "Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Despite the success of treatment of CVD with statin therapy, a number of patients remain at high risk for CVD. Ezetimibe is a non-statin agent that inhibits intestinal cholesterol absorption, leading to reductions in low-density lipoprotein cholesterol (LDL-C). A number of clinical studies evaluating the use of ezetimibe therapy have resulted in discordant data regarding its safety and efficacy. In this review, we discuss the findings from these studies as well as potential indications for the use of ezetimibe for LDL-C lowering and cardiovascular event reduction.",

keywords = "Cardiovascular disease, Ezetimibe, Low-density lipoprotein cholesterol",

author = "Anandita Agarwala and Zaid Kajani and Miedema, \{Michael D.\} and Virani, \{Salim S.\}",

note = "Publisher Copyright: {\textcopyright} Springer Science+Business Media New York (outside the USA) 2016.",

year = "2016",

month = feb,

doi = "10.1007/s11883-016-0560-y",

language = "English (UK)",

volume = "18",

journal = "Current Atherosclerosis Reports",

issn = "1523-3804",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - The role of ezetimibe in the treatment of cardiovascular disease

AU - Agarwala, Anandita

AU - Kajani, Zaid

AU - Miedema, Michael D.

AU - Virani, Salim S.

N1 - Publisher Copyright: © Springer Science+Business Media New York (outside the USA) 2016.

PY - 2016/2

Y1 - 2016/2

N2 - Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Despite the success of treatment of CVD with statin therapy, a number of patients remain at high risk for CVD. Ezetimibe is a non-statin agent that inhibits intestinal cholesterol absorption, leading to reductions in low-density lipoprotein cholesterol (LDL-C). A number of clinical studies evaluating the use of ezetimibe therapy have resulted in discordant data regarding its safety and efficacy. In this review, we discuss the findings from these studies as well as potential indications for the use of ezetimibe for LDL-C lowering and cardiovascular event reduction.

AB - Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Despite the success of treatment of CVD with statin therapy, a number of patients remain at high risk for CVD. Ezetimibe is a non-statin agent that inhibits intestinal cholesterol absorption, leading to reductions in low-density lipoprotein cholesterol (LDL-C). A number of clinical studies evaluating the use of ezetimibe therapy have resulted in discordant data regarding its safety and efficacy. In this review, we discuss the findings from these studies as well as potential indications for the use of ezetimibe for LDL-C lowering and cardiovascular event reduction.

KW - Cardiovascular disease

KW - Ezetimibe

KW - Low-density lipoprotein cholesterol

UR - https://www.scopus.com/pages/publications/84978829804

U2 - 10.1007/s11883-016-0560-y

DO - 10.1007/s11883-016-0560-y

M3 - Article

C2 - 26792014

AN - SCOPUS:84978829804

SN - 1523-3804

VL - 18

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

IS - 2

M1 - 8

ER -

The role of ezetimibe in the treatment of cardiovascular disease

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this